International Conference on

Orphan Drugs & Rare Diseases

Berlin, Germany   March 16-17, 2020

GET THE APP

Orphan Drugs 2020

Theme: A step towards advancement in the research and treatment of rare diseases

Orphan Drugs 2020 Conference is delighted to welcome the participants from all over the world to attend the prestigious International Conference on Orphan Drugs & Rare Diseases scheduled during March 16-17, 2020 at Berlin, Germany which based on the theme "A Step Towards Advancement in The Research and Treatment of Rare Diseases".

Scientific sessions of Orphan Drugs 2020 includes orphan drugs, clinical research on orphan drugs, challenges in rare Diseases treatment, Immunological Rare Diseases, Rare Oncology, Rare Neurological Disorders.

Berlin is the capital and the leading city of Germany. The destinations which makes Berlin special are Alexander platz, Berlin Bei Nacht, Berlin Cathedral, Berlin TV Tower, Brandenburg Gate, Charlottenburg Palace and Park, Oberbaum Bridge, Museum Island, The Rebuilt Reichstag.

Scientific Sessions 

An orphan drug is a pharmaceutical agent developed to treat medical conditions. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.
 
A clinical trial is a medical study performed to check the effects of a new or already existing drug, of a biological cure or of a clinical gadget that might deal with or curb a ailment already identified. The most important aim of a clinical trial is to evaluate two or various organizations of subjects, by means of using two or a number of remedies in order to determine the efficacy of a drug or of a biological treatment. Clinical trials are carefully and ethically performed in order to protect sufferers towards unwanted adverse reactions and to allow series and accurate analysis of the information concerning the disease.
 
This track outlines the ethical dilemma of funding orphan drug lookup and development. To date, moral aspects of precedence placing for research funding have now not been an issue of dialogue in the bioethics debate. Conflicting ethical responsibilities of beneficence and distributive justice appear to demand very different degrees of funding for orphan drug research.
 
An orphan drug is referred medicinal agent which has been developed to treat a extraordinary scientific ailment or situation, the state of affairs itself being described to as a uncommon disease. Rare disease, additionally recognized as an "orphan disease", is any kind of sickness which affects a small share of the population. Majority of distinguished ailments are genetic, and as a end result are present in the path of the individual's whole life, even if symptoms doesn’t exhibit up immediately. Many individual ailments exhibit up early in life, and about two 30 % of teenagers with uncommon diseases will die before getting 5 year old. two An health problem might also be considered distinct in one area of the world, or in a team of people, then again nevertheless be ordinary in any other use or crew of people.
 
As per the brand new researches, the orphan drug market is now opening to display traits viewed in typical pharma markets. The vary of orphan drug approvals have expanded in current years. Both novel entrepreneurs and new warning symptoms serve as the predominant drivers of this cutting-edge orphan drug growth. The new industrial agency model of orphan drugs may want to offer a cohesive healthcare decision that allows pharma groups to enhance extra current areas of therapeutics, analysis, treatment, monitoring, and affected person support. Additionally, the improvement of orphan tablets is faced with some challenges that are unique to wonderful diseases. In spite of the challenges, innovative Competitive Intelligence (CI) strategies can provide an attentive and increased approach for the worthwhile development of orphan drugs.
 
An uncommon ailment is characterized as a condition that influences under 200,000 individuals. This clarification was shaped by Congress in the Orphan Drug Act of 1983. There might be upwards of 7,000 uncommon infections. Just a couple of classifications of uncommon infections are followed when an individual is analyzed. These incorporate certain irresistible infections, birth imperfections, and diseases.
 
A scientific take a look at is an experimentation supposed to figure out extraordinary logical and consequence parts of proposed treatment. It is indispensable to recollect that there is no certification a proposed therapy will be compelling. Families ought to be set up to regulate the desire for partaking in a scientific preliminary with the perception that the therapy might also now not be best and should end result in a authentic poor result.
 
The immune gadget is delegated to defend the body from assaults from backyard or inside. Many diseases can have an effect on immune system decreasing its capability to defend self or inducing an peculiar response against exterior or inner antigens. Rare diseases affecting immune system current some difficulty in frequent with different rare diseases and some peculiarities due to the large variability in the disease's expression.
 
The wide vary of types of extraordinary oncological illnesses incorporate tumors of the body and hematological problem of the blood. Albeit solely these malignancies are uncommon, as a gathering, they talk to a noteworthy large part of humans with cancer. Certain attributes of these malignancies separate them from step by step basic kinds of disease.
 
Many rare diseases currently have little to no effective measures of diagnoses and treatments, primarily due to lack of representative patients and funding towards researching rare disease pathogenesis. For instance, a large group of rare diseases that have ineffective diagnoses and treatments are the neurological disorders. These disorders target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. 
 
Determination and the remedy of an exclusive sickness end up complicated due to the prerequisites that a number of human offerings suppliers may have restricted inclusion with the recognizable proof of the illness circumstance with the finding of extraordinary infections. Moreover, investigation earlier than sign starting or conclusion commencing time in the contamination can be testing. A scientific take a look at is an experimentation meant to decide distinctive logical and outcome parts of proposed treatment. It is crucial to recollect that there is no certification a proposed remedy will be compelling. Families ought to be set up to alter the want for partaking in a scientific preliminary with the grasp that the remedy can also now not be best and may want to end result in a authentic terrible result.

 

Meetings International & Orphan Drugs 2020 offers several awards given to recognize outstanding scholarly contributions to the field of international studies. These awards have different committees, nominating procedures and submission deadlines. They recognize Best Key Note Speaker Award, Outstanding Speaker Award, Best Organising Committee Member Award, Outstanding Masters/Ph.D/Post. Doc Thesis work presentation Award & Best Poster Award.

Best Key Note Speaker Award: Orphan Drugs 2020 will honours the Keynote Speakers who have made significant contributions to the field of information systems but also makes a difference by his presence during the conference. Recipients of the award are considered to have advanced the field through research or service.

Outstanding Speaker Award: Orphan Drugs 2020 perceives the individuals who have made significant and imaginative walks in education system. This honour perceives advancement in instructing methodologies and strategies just as in conveying oral presentation in conference. This honour explicitly centers around the uniqueness and creativity that expands members interests.

Best Organising Committee Member Award: Meetings International will honour the individual who has demonstrated exemplary support and guidance throughout the conference.

Outstanding Masters/Ph.D/Post. Doc Thesis Work Presentation Award: This award recognizes individuals in the early stages of their careers who have already made outstanding research, teaching, and/or service contributions to the field of information systems.

Best Poster Award: This award recognizes individuals from poster presenters who have display their outstanding research and findings for an innovative future. Recipients of the award are considered to be the Best Poster Presenter of the conference.

Criteria:

  • All presented abstracts will automatically be considered for the Award.
  • All the presentation will be evaluated in the conference venue
  • All the awards will be selected by the judges of the award category
  • The winners will be formally announced during the closing ceremony.
  • The winners of the Poster Award will receive award certificate.
  • The awards will be assessed as far as plan and format, intelligence, argumentation and  approach, familiarity with past work, engaging quality, message and primary concerns, parity of content visuals, and by and large impression.

Guidelines:

  • All submissions must be in English.
  • The topic must fit into scientific sessions of the conference
  • Each individual participant is allowed to submit maximum 2 papers
  • Abstract must be submitted online as per the given abstract template
  • Abstracts must be written in Times New Roman and font size will be 12
  • Abstract must contain title, name, affiliation, country, speakers biography, recent photograph, image and reference
  • Each poster should be approximately 1x1 M long. The title, contents and the author’s information should be clearly visible from a distance of 1-2 feet.

 

Meetings International is announcing Young Scientist Awards through International Conference on Orphan Drugs and Rare Diseases (Orphan Drugs 2020) which is scheduled at Berlin, Germany during March 16-17, 2020. This Orphan Drugs conference focuses on “A step towards advancement in the research and treatment of rare diseases”.

Orphan Drugs 2020 and upcoming conferences will recognise participants who have significantly added value to the scientific community of environmental science and provide them outstanding Young Scientist Awards. The Young Scientist Award will provide a strong professional development opportunity for young researches by meeting experts to exchange and share their experiences at our international conferences.

Orphan Drugs 2020 focuses mainly on Orphan Drugs, Clinical Research on Orphan Drugs, Challenges in Rare Diseases Treatment, Immunological Rare Diseases, and Rare Oncology. Orphan Drugs conference operating committee is providing a platform for all the budding young researchers, young investigators, post-graduate/Master students, PhD. students and trainees to showcase their research and innovation.

Eligibility:

Young Scientists, faculty members, post-doctoral fellows, PhD scholars and bright Final Year MSc and M.Phil. Candidates. Persons from Scientific Industry can also participate.

Benefits: The Young Scientist Feature is a platform to promote young researchers in their respective area by giving them a chance to present their achievements and future perspectives.

  • Acknowledgement as YRF Awardee
  • Promotion on the conference website, Young Researcher Awards and certificates
  • Link on the conference website
  • Recognition on Meetings Int. Award Page
  • Chances to coordinate with partners around the world
  • Research work can be published in the relevant journal without any publication fee

Criteria:

  • All presented abstracts will automatically be considered for the Award.
  • All the presentation will be evaluated in the conference venue
  • All the awards will be selected by the judges of the award category
  • The winners of the Young Scientist Award will receive award certificate.
  • The awards will be assessed as far as plan and format, intelligence, argumentation and  approach, familiarity with past work, engaging quality, message and primary concerns, parity of content visuals, and by and large impression.

Guidelines:

  • All submissions must be in English.
  • The topic must fit into scientific sessions of the conference
  • Each individual participant is allowed to submit maximum 2 papers
  • Abstract must be submitted online as per the given abstract template
  • Abstracts must be written in Times New Roman and font size will be 12
  • Abstract must contain title, name, affiliation, country, speakers biography, recent photograph, image and reference

Conditions of Acceptance:

To receive the award, the awardee must submit the presentation for which the award is given, for publication at the website, along with author permission. Failure to submit the PPT, and permission within the designated timeframe will result in forfeiture of award.

Award Announcements:

Official announcement of the recipients will occur after the completion of Orphan Drugs Conference.

 

Market Analysis
Introduction
An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.
 
Why to organize this conference?
 
1. To share learning and best follow from thought leaders and specialists in the field of Orphan Drugs
2. To engage with compatible individuals with shared interests 
3. To inspire and generate awarness to Rare diseases
4. To make a discussion about the diseases and betterment of its treatment
5. To form new partnerships all over the world 
6. To get results and diffuse messages face to face in an exceedingly value effective manner 
7. To provoke action and collectively bring the evolution in the field of Rare Diseases and its treatment
8. To network and meet new people and organisations who are professional in the field of Orphan Drugs
9. To encourage PR and media coverage
 
Importance & Scope
 
There are greater than 6000 Rare Diseases. Many rare diseases are identified at the age of childhood, making diagnostic awareness and understanding on treatment and care specifically necessary for pediatricians. The Rare Diseases are so rare that rarity can lead to various troubles including: difficulties in obtaining timely, correct diagnoses; lack of experienced healthcare supervisors; useful, dependable and well timed statistics may additionally be challenging to retrieve; lookup things to do are very less; growing new prescribed drugs can also not be economically feasible; treatments are on occasion very expensive; and in developing countries, the issues are compounded via different resource limitations.
 
Orphan Drug 2020 is emerging up with an exciting and excessive knowledge gaining convention application this yr also which includes plenary lectures, symposia, workshops on a range of topics, poster shows and a number packages for contributors from at some stage in the world. We welcome you to join us at the International Conference on Orphan Drugs and Rare Diseases in Berlin the place you will be sure to have a significant ride with scholars from around the world. The Rare Diseases Conference aims to extend the reach, impact and trade of scholarly thoughts via revolutionary technology, determined commitment and awesome service. It objectives to provide international collaboration and trade of complete and ultra-modern data on basic, translational, and utilized medical research on Rare iseases and Orphan Drugs. The field of rare disease products is continuously growing, expecting to reach $180 billion by 2020, with a CGR of 10.5% just for orphan drugs – this is twice the growth rate of the overall prescription drug market.
 
Top Global Universities
 
America
  • Columbia University Medical Center, Columbia
  • New York University School of Medicine, New York
  • Stanford University Medical Center, California,america
  • University of Massachusetts Medical School, Massachusetts,america
  • University of Texas Southwestern Medical Center, Texas,America
  • East Carolina University, North Carolina
  • East Tennessee State University, Tennessee
  • University of Pittsburgh Medical Center, Pittsburgh
  • Texas Medical Center, Texas
  • Columbia University Department of Middle Eastern, South Asian, and African Studies, New York
 
Europe
  •  University of Birmingham, United Kingdom
  • Paracelsus Medical University, Austria
  • Grodno State Medical University, Belarus
  • Medical University of Varna, Bulgaria
  • University of Strasbourg, France
  • University of Patras, Greece
  • National University of Ireland, Galway
  • Biomedical University of Rome, Italy
  • Medical Sciences Division, University of Oxford, England
  • Charité – University Medicine Berlin, Germany
  • Freie Universitat Berlin, Germany
  • Humboldt University of Berlin, Germany
  • University of Eastern Piedmont, Italy
  • Poznan University of Medical Sciences, Poland
  • Rostov State Medical University, Russia 
  • Albert Szent-Györgyi Medical University, Europe
  • Ternopil National Medical University, Ukraine
  • Bukovinian State Medical University,  Ukraine
  • Ternopil National Medical University, Ukraine
  • Dnipro Medical Institute of Conventional and Alternative Medicine, Ukraine
  • Donetsk National Medical University, Ukraine
 
Asia-Pacific
  • Asia University, Taiwan
  • International Medical University, Malaysia
  • Gulf Medical University, United Arab Emirates
  • Columbia University Medical Center, United Arab Emirates
  • University Malaya Medical Centre, Malaysia
  • Goa Medical College, India
  • Rajiv Gandhi University of Health Sciences, India
  • Tokyo Medical University, Japan
  • Yerevan State Medical University, Armenia 
  • Wenzhou Medical University, China
  • King Edward Medical University, Pakistan
  • Capital University of Medical Sciences, China
 
Middle East
  • Middle East Technical University, Turkey
  • Biomedical research in the Middle East
  • Shandong University
  • Hacettepe University Medical School, Turkey
 

Global Research Centers

America
  • De La Salle Medical and Health Sciences Institute
  • South Texas Medical Center
  • Boston Medical Center
  • University of Texas Southwestern Medical Center
  • University of Cincinnati Academic Health Center
  • Stanford University Medical Center
  • UCSF Medical Center
  • Federal Medical Center, Carswell
  • Vydehi Institute of Medical Sciences and Research Centre
  • Texas Medical Center
Europe
  • U.S. Army Medical Materiel Center – Europe
  • City of Hope National Medical Center
  • VU University Medical Center
  • University of Texas MD Anderson Cancer Center
  • University Medical Center Freiburg
  • BaÅŸkent University Medical and Research Center of Alanya
  • United States Army Medical Research and Materiel Command
  • VCU Medical Center
  • United States Army Medical Research Institute of Infectious Diseases
  • Fitzsimons Army Medical Center
  • United States Army Medical Command
Asia-Pacific
  • Naval Medical Research Center
  • Rajiv Gandhi Cancer Institute and Research Centre
  • University of Texas MD Anderson Cancer Center
  • California National Primate Research Center
  • West China Medical Center
  • Columbia University Medical Center
  • Capitol Medical Center
  • National Institute of Virology
  • Naval Medical Center San Diego
  • LAC+USC Medical Center
Middle East
  • Biomedical research in the Middle East
  • Medical centers in the United States
  • BaÅŸkent University Medical and Research Center of Alanya
  • Sheba Medical Center
  • University of Utah Middle East Center
  • Naval Medical Research Unit Three
  • Columbia University Medical Center
  • David Grant USAF Medical Center
  • National Center for Medical Intelligence
  • Middle East Cancer Consortium
Hospitals Associated with Rare Diseases Research Worldwide
 
USA
  • The Manton Center for Orphan Disease Research
  • US hospital for rare disease research
  • Chicago Rare Disease Foundation
  • National Institute of Health (NIH) funds research consortia to study more than 200 rare diseases
  • Children’s Hospital of Pittsburgh (Center for Rare Disease Therapy)
  • The Children’s Hospital of Philadelphia
  • The Christ Hospital
  • Medical City Dallas Hospital
  • Barnes-Jewish Hospital
  • Middlesex Hospital (Connecticut)
  • Massachusetts General Hospital
Europe
  • Johns Hopkins Hospital
  • Massachusetts General Hospital
  • Charitée
  • University College London Hospitals NHS Foundation Trust
  • Birmingham children’s Hospital (NHS Foundation Trust)
  • University Hospital of Wales
  • Medical Center Leeuwarden
  • NewYork–Presbyterian Hospital
  • Helsinki University Central Hospital
  • Yale New Haven Hospital
  • St. Olav's University Hospital
  • Aarhus University Hospital
Asia-Pacific
  • Ahmedabad Civil Hospital
  • Beijing Hospital of Traditional Chinese Medicine
  • Dhaka Medical College Hospital
  • West China Hospital
  • Bumrungrad International Hospital
  • Fortis Hospital
  • Asan Medical Centre (AMC)
  • Buddhist Tzu Chi Medical Foundation
  • National Hospital Organisation Medical centre
  • Prince Court Medical Centre (PCMC)
  • Gleneagles Hospital
  • Hong Kong Sanatorium and Hospital (HKSH)
  • Luke’s Medical centre
  • Wooridul Spine Hospital
  • King’s College Hospital London – Dubai Hills
Middle East
  • Clinic for Health and Medical Care
  • Magrabi Hospitals and Centers
  • IHH Healthcare
  • Magrabi Hospitals and Centers
  • American Hospital
  • NMC Hospital Group
  • Mediclinic Middle East (EHL HealthCare Management Services)
  • Holistic Healing Medical Centre
  • Mediclinic Al Jowhara Hospital
  • Mediclinic Al Mamora
Fund Allotment to Rare Diseases Research
Physician-scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases. The collaborations are made possible through awards by the National Institutes of Health — totaling about $29 million in the fiscal year 2014 funding — to expand the Rare Diseases Clinical Research Network (RDCRN), which is led by NIH’s National Center for Advancing Translational Sciences (NCATS).

References

  1. https://en.wikipedia.org/wiki/Orphan_drug
  2. https://en.wikipedia.org/w/index.php?title=Special:Search&limit=20&offset=20&ns0=1&search=middle+east+medical+research+center&advancedSearch-current={}
  3. https://en.wikipedia.org/w/index.php?sort=relevance&search=usa+medical+research+center&title=Special%3ASearch&profile=advanced&fulltext=1&advancedSearch-current=%7B%7D&ns0=1
  4. https://en.wikipedia.org/w/index.php?sort=relevance&search=europe+medical+research+center&title=Special:Search&profile=advanced&fulltext=1&advancedSearch-current=%7B%7D&ns0=1
  5. https://en.wikipedia.org/w/index.php?sort=relevance&search=Asia+pecific+medical+university&title=Special%3ASearch&profile=advanced&fulltext=1&advancedSearch-current=%7B%7D&ns0=1
  6. https://en.wikipedia.org/w/index.php?sort=relevance&search=USA+medical+university&title=Special%3ASearch&profile=advanced&fulltext=1&advancedSearch-current=%7B%7D&ns0=1
 

 

  • Orphan Drugs
  • Clinical Research on Orphan Drugs
  • Orphan Drugs and Ethical Issues
  • Orphan Drugs and Potentiality
  • Orphan Drugs strategies and developmental trends
  • Challenges in Rare Diseases Treatment
  • Clinical Case Studies on Rare Diseases
  • Immunological Rare Diseases
  • Rare Oncology
  • Rare Neurological Disorders
  • Treatment and Advanced Therapies for Rare Diseases

7 Organizing Committee Members

6 Renowned Speakers

Niccola Funel

University of Pisa Italy
Italy

Sorush Niknamian

University Blvd, Lynchburg, USA
USA

Duska Petranovic

University of Rijeka, Croatia
Croatia

Augusta Elizabeth Koroma

Anglia Ruskin University, UK
UK

Husham Bayazed

University of Zakho, Iraq
Iraq

Kazuko Tatsumura

Gaia Holistic Health USA and Japan
USA

Media Partners & Collaborations

  • Media Partner

  • Media Partner

  • Media Partner

  • Media Partner

  • Media Partner

  • Media Partner